Clinical trial NCT02701569: Effect of Rebound Exercise in Individuals With Type 2 Diabetes
Official title: Effect of Rebound Therapy on Metabolic Outcomes and Quality of Life in Nigerian Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: University of KwaZulu
Sponsor class: OTHER
Collaborators: name: Aminu Kano Teaching Hospital
First posted: 2016-03-08
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to investigate the effect of rebound exercise (mini trampoline jumping) on metabolic outcomes and quality of life in patients with Type 2 Diabetes.

Detailed description: The exercise involved jumping on the mini trampoline with feet slightly apart. Participants stood on the mid portion of the trampoline bed and made repeated up-and-down bouncy movements. Each foot strike equals one step or bounce. With each landing, the mat of the trampoline underwent deformation and the springs released the energy stored in them such that the participant was made to bounce off the mat. Exercise was administered for between 10 - 15 minutes after which a 5-minute period of rest was allowed. A heart rate monitor was used to guide the intensity of the exercise in the moderate range. Each participant accumulated between 20 and 30 minutes of rebound exercise (bouncing on a mini trampoline) per session, administered three times per week for 12 weeks. All data were captured at baseline and at the end of the 12-week intervention period.

Eligibility criteria: Inclusion Criteria:

* 30- to 60-year-old male and female individuals;
* A diagnosis of type 2 diabetes ≤ 5 years;
* Attendance at the Diabetes Outpatient Clinics of Aminu Kano Teaching Hospital and Murtala Muhammad Specialist Hospital in Kano, Northwestern Nigeria;
* Self-ambulatory;
* An inactive lifestyle over the last year.

Exclusion Criteria:

* A diagnosis of type 2 diabetes for more than 5 years;
* Hypertension (systolic and diastolic blood pressure more than 140 and 90 mmHg, respectively) or treatment for hypertension;
* Use of insulin therapy
* Lower limb weakness and/or deformities with loss of protective sensation in the feet;
* Back, shoulder or knee problems and/or joint instability;
* History of coronary artery disease, retinopathy and nephropathy;
* Myocardial infarction, cardiac or abdominal surgery within the previous 6 months;
* History of fractures of the spine, hip, knee and/or ankle joints.

Primary outcomes:
measure: Glycated hemoglobin
timeFrame: 3 months
Secondary outcomes:
measure: Fasting plasma glucose
timeFrame: 3 months
measure: Fasting insulin
timeFrame: 3 months
measure: High-density lipoprotein cholesterol
timeFrame: 3 months
measure: Total cholesterol
timeFrame: 3 months
measure: Triglycerides
timeFrame: 3 months
measure: Low-density lipoprotein cholesterol
timeFrame: 3 months
measure: Quality of life
timeFrame: 3 months
measure: Body mass
timeFrame: 3 months
measure: Height
timeFrame: 3 months
measure: Heart rate
timeFrame: 3 months
measure: Respiratory rate
timeFrame: 3 months
measure: Blood pressure
timeFrame: 3 months
measure: Maximal oxygen consumption
timeFrame: 3 months
measure: Diabetes-related emotional distress as measured by the Problem Areas in Diabetes Scale
timeFrame: 3 months
measure: Well-Being as measured by the World Health Organization-Well-Being Index
timeFrame: 3 months
measure: Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire
timeFrame: 3 months
Other outcomes:
measure: Depressive symptoms as measured by the Beck's Depression Inventory
timeFrame: 3 months
Locations:
Study officials:
affiliation: UKZN
name: Sonill S Maharaj, PhD
role: STUDY_CHAIR
References: